Abstract
Medical treatment of heroin addiction with methadone and other pharmacotherapies has important benefits for individuals and society. However, regulatory policies have separated this treatment from the medical care system, limiting access to care and contributing to the social stigma of even effective addiction pharmacotherapy. Increasing problems caused by heroin addiction have added urgency to the search for policies and programs that improve the access to and quality of opiate addiction treatment. Recent initiatives aiming to reintegrate methadone maintenance and other addiction pharmacotherapies into medical practice may promote both expanded treatment capacity and increased physician expertise in addiction medicine. These initiatives include changes in federal oversight of the opiate addiction treatment system, the approval of physician office-based methadone maintenance programs for stabilized patients, and federal legislation that could enable physicians to treat opiate addiction with new medications in regular medical practice.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
Office of National Drug Control Policy. National drug control strategy. Washington, DC: Office of National Drug Control Policy; 2000.
Solet D, Hagan H, Nakaguwara J, Plough A, Ball JK. Unintentional opiate overdose deaths — King County, Washington, 1990–1999. Morb Mortal Wkly Rep. 2000;49:636–8.
Oxman GL, Kowalski S, Drapela L, et al. Heroin overdose deaths — Multinomah County, Oregon, 1993–1999. Morbid Mortal Wkly Rep. 2000;49:633–6.
Drug Abuse Warning Network Annual Medical Examiner Data 1999. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Web site. Available at: http://www.samhsa.gov/oas/DAWN/99me_annual.pdf. Accessed March 15, 2002.
Bach PB, Lantos J. Methadone dosing, heroin affordability, and the severity of addiction. Am J Public Health. 1999;89:662–5.
Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001; 61:195–206.
Meadows M. Prescription drug use and abuse. FDA Consum. 2001;35:18–24. Available at: http://www.fda.gov/fdac/features/2001/501_drug.html. Accessed March 15, 2002.
Community Epidemiologic Work Group. Epidemiologic Trends in Drug Abuse: Advance Report. Rockville, Md: National Institute on Drug Abuse; 2001.
National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280:1936–43.
Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. JAMA. 2000;283:1337–9.
Musto DF. The American Disease: Origins of Narcotic Control. Expanded ed. New York: Oxford University Press; 1987.
Massing M. The Fix. New York: Simon and Schuster; 1998.
Rettig RA, Yarmolinsky A, eds. Federal Regulation of Methadone Treatment. Washington, D.C: National Academy Press; 1995.
Spunt B, Hunt D, Lipton D, Goldsmith D. Methadone diversion: a new look. J Drug Issues. 1986;18:569–83.
Barrett DH, Luk AJ, Parrish RG, Jones TS. An investigation of medical examiner cases in which methadone was detected, Harris County, Texas, 1987–1992. J Forensic Sci. 1996;41:442–8.
Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965;193:80–4.
Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 1981;7: 249–56.
Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485–8.
Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221–6.
Ball J. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcomes. New York: Springer-Verlag; 1991.
Caplehorn JR, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust. 1991;154:195–9.
Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993;119:23–7.
Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate-vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000–5.
Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000; 283:1303–10.
Hubbard RL, Marsden ME, Rachel JV. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill: University of North Carolina Press; 1989.
Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA. 1988;260:3025–9.
Stimmel B, Kreek MJ. Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med. 2000;67: 375–80.
McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689–95.
D’Aunno T, Vaughn TE. Variations in methadone treatment practices. Results from a national study. JAMA. 1992;267: 253–8.
Cooper JR. Ineffective use of psychoactive drugs. Methadone treatment is no exception. JAMA. 1992;267:281–2.
Parrino MW. State Methadone Treatment Guidelines. Treatment improvement protocol (TIP) series no 1. Rockville, Md: Center for Substance Abuse Treatment; 1993.
Wilson P, Watson R, Ralston GE. Methadone maintenance in general practice: patients, workload, and outcomes. BMJ. 1994; 309:641–4.
Peters AD, Reid MM. Methadone treatment in the Scottish context: outcomes of a community-based service for drug users in Lothian. Drug Alcohol Depend. 1998;50:47–55.
Hutchinson SJ, Taylor A, Gruer L, et al. One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. Addiction. 2000;95:1055–68.
Brewer C. Recent developments in maintenance prescribing and monitoring in the United Kingdom. Bull NY Acad Med. 1995;72: 359–70.
Gruer L, Wilson P, Scott R, et al. General practitioner-centred scheme for treatment of opiate-dependent drug injectors in Glasgow. BMJ. 1997;314:1730–5.
Klingemann HK. Drug treatment in Switzerland: harm reduction, decentralization and community response. Addiction. 1996;91: 723–36.
Caplehorn J, Batey R. Methadone maintenance in Australia. J Drug Issues. 1992;22:661–79.
Byrne A, Wodak A. A census of patients receiving methadone treatment in a general practice. Addict Res. 1996;3:341–9.
College of Physicians and Surgeons of Ontario. Methadone Maintenance Guidelines. Toronto: The College of Physicians of Ontario; 1996.
World Health Organization Programme on Substance Abuse Substitution Project. Report of WHO Consultation, Geneva, 15–9 May 1995. Geneva: World Health Organization; 1996.
Morrison C. Obstetric liason in drug dependency. Addict Res. 1995;3:93–101.
Greenwood J. Persuading general practitioners to prescribe — good husbandry or a recipe for chaos? Br J Addict. 1992;87:567–75.
Greenwood J. Creating a new drug service in Edinburgh. BMJ. 1990;300:587–9.
Hall D. The Demand for Methadone Maintenance Treatment in Australia. National Drug and Alcohol Research Center, Technical Report No. 28. Sydney, Australia: National Drug and Alcohol Research Center; 1995.
Ward J, Mattick RP, Hall D. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Amsterdam: Harwood Academic Publishers; 1998.
Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for US policy. JAMA. 2000;283:1343–8.
Drummer OH, Opeskin K, Syrjanen M, Cordner SM. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. Am J Forensic Med Pathol. 1992;13: 346–50.
Strang J, Sheridan J. Methadone prescribing to opiate addicts by private doctors: comparison with NHS practice in southeast England. Addiction. 2001;96:567–76.
Fountain J, Strang J, Gossop M, Farrell M, Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction. 2000;95:393–406.
Substance Abuse and Mental Health Services Administration. Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction; Final Rule. Fed Regist. 2001;66:4075–102.
Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000; 343:1290–7.
Glanz M, Klawansky S, McAullife W, Chalmers T. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials. Am J Addict. 1997;6:339–49.
Salsitz EA, Joseph H, Frank B, et al. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice—a summary report (1983–1998). Mt Sinai J Med. 2000;67:388–97.
Schwartz RP, Brooner RK, Montoya ID, Currens M, Hayes M. A 12-year follow-up of a methadone medical maintenance program. Am J Addict. 1999;8:293–9.
Senay EC, Barthwell A, Marks R, Bokos PJ. Medical maintenance: an interim report. J Addict Dis. 1994;13:65–9.
Fiellin DA, O’Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001;286:1724–31.
Lepay D, Clark HW. Federal Advisory on Methadone Medical Maintenance Exemptions. Rockville, Md: U.S. Department of Health and Human Services; 2000.
San Francisco Department of Public Health. A Program for Physician Prescription of Methadone in San Francisco. San Francisco, Calif: San Francisco Department of Public Health; 1999. Available at: http://www.dph.sf.ca.us/Reports/methrep.pdf. Accessed March 15, 2002.
Drucker E, Hartel D, Tuchman E, Bonuck K, Vavaglakis P, McCarthy W. Office Based Methadone Prescribing In Primary Care: Results of a Randomized Clinical Trial of Safety and Efficacy. San Juan, Puerto Rico: College on Problems of Drug Dependence; 2000.
Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475–86.
Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54:713–20.
O’Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105:100–5.
Fhima A, Henrion R, Lowenstein W, Charpak Y. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex). Ann Med Interne (Paris). 2001;152(Suppl 3):IS26–36.
Vignau J, Brunelle E. Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results. Eur Addict Res. 1998; 4(Suppl 1):24–8.
Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction. 2001; 96:267–72.
Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA. 2001;285:45.
Saitz R, Mulvey KP, Plough A, Samet JH. Physician unawareness of serious substance abuse. Am J Drug Alcohol Abuse. 1997;23: 343–54.
Hasin DS, Grant BF, Dufour MG, Endicott J. Alcohol problems increase while physician attention declines. 1967 to 1984. Arch Intern Med. 1990;150:397–400.
Stimmel B. Appropriate training in alcohol and substance abuse for primary care physicians: defining the problem. In: Sirica C, ed. Training about Alcohol and Substance Abuse for All Primary Care Physicians. A Conference Sponsored by the Josiah Macy, Jr. Foundation, chaired by David C. Lewis, Phoenix, Arizona, October 2–5, 1994. New York: Josiah Macy, Jr. Foundation; 1995:249–74.
Fiellin DA, Storti SA, Schottenfeld RS, Biscoe JD, Pantalon MV, O’Connor PG. Methadone medical maintenance: a training and resource guide for office-based physicians. Vol. 2001: New England Addiction Technology Transfer Center; 2000. Available at http://www.caas.brown.edu/ATTC-NE/pubs/OBOT/. Accessed 11/24/01.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was assisted by a grant from the Robert Wood Johnson Foundation Substance Abuse Policy Research Program.
Rights and permissions
About this article
Cite this article
Merrill, J.O. Policy progress for physician treatment of opiate addiction. J GEN INTERN MED 17, 361–368 (2002). https://doi.org/10.1007/s11606-002-0041-6
Issue Date:
DOI: https://doi.org/10.1007/s11606-002-0041-6